Clinical trials: Thiotepa
Brain and Central Nervous System Tumors, Lymphoma
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00621036
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Brain and Central Nervous System Tumors
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or…
- Trial name
- NCT00003101
- Testing
- filgrastim, busulfan, lomustine
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Retinoblastoma
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)
Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to histopathological risk factors of the International Retinoblastoma Staging Working Group.
- Trial name
- RB SFCE 09 (NCT02870907)
- Testing
- Observation, Etoposide, Vincristine
- Where
- 27 sites in France
- Volunteers
- 195 people
- Sponsor
- Institut Curie
Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment
Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
High-dose methotrexate (HD-MTX) remains the foundation of treatment for primary central nervous system lymphoma (PCNSL), but outcomes are suboptimal.
- Trial name
- NCT06946407
- Testing
- Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
- Where
- China
- Volunteers
- 41 people
- Sponsor
- FengYan Jin
Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT05931328
- Testing
- thiotepa combined with pomalidomide
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
High-risk Medulloblastoma
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
The trial includes i) the evaluation of the efficacy of a treatment strategy, designed as a phase II trial, and ii) a dose-finding part.
- Trial name
- HR MB-5 (NCT02025881)
- Testing
- Carboplatin + etoposide, Thiotepa, Cyclophosphamide + Busilvex
- Where
- 13 sites in France
- Volunteers
- 29 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Sickle Cell Disease, Graft Versus Host Disease
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving…
- Trial name
- NCT02867800
- Testing
- Diphenhydramine, Acetaminophen, Methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Monica Bhatia
Leukemia, Myelodysplastic Syndromes
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
RATIONALE: Giving total-body irradiation and chemotherapy, such as fludarabine and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00392782
- Testing
- anti-thymocyte globulin, fludarabine phosphate, thiotepa
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
HLH
Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement
EBV-HLH is the most common in virus-associated hemophagocytic syndrome (VAHS). There are no uniform clinical criteria for the diagnosis of CNS-HLH.
- Trial name
- NCT05854225
- Testing
- Thiotepa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Lymphoma
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma.
- Trial name
- NCT01511562
- Testing
- carmustine, cytarabine, etoposide
- Where
- 126 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
- Conditions
- Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders
- Trial name
- FAM BMT (NCT03128996)
- Testing
- RIC regimen, GVHD prophylaxis regimen
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Washington University School of Medicine
Wiskott-Aldrich Syndrome
Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome
Wiskott - Aldrich syndrome (WAS) is a rare disorder curable only through allogeneic hematopoietic stem cell transplantation. A mismatched family member is an option when no human leukocyte antigen (HLA-immune system type) matched…
- Trial name
- NCT00160355
- Testing
- Hematopoietic stem cell transplantation, Miltenyi CliniMACS selection system, Fludarabine, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Medulloblastoma, Central Nervous System Embryonal Tumors
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
This is a prospective randomized clinical trial, to determine whether dose-intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival…
- Trial name
- NCT02875314
- Testing
- Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
- Where
- 62 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Parth Patel